Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer

  • End date
    Jul 27, 2022
  • participants needed
  • sponsor
    Memorial Sloan Kettering Cancer Center
Updated on 27 January 2021
ct scan
karnofsky performance status
endocrine therapy
progressive disease
hormone therapy
bone scan
metastatic prostate cancer
positron emission tomography
pet/ct scan
prostate cancer metastatic


The purpose of this study is to determine if Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) scans used in this study accurate and better at imaging participants' prostate cancer than the usual methods.

Condition Malignant neoplasm of prostate, Prostatic disorder, Prostate Disorders, Prostate Cancer, Early, Recurrent, Prostate Adenocarcinoma, Adenocarcinoma of the Prostate, Adenocarcinoma of Prostate, Metastatic Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer, prostate carcinoma, prostate neoplasm, prostate tumor, prostate tumors, prostate cancers
Treatment PET/CT scan, 18F-DCFPyL-iPSMA, 68Ga-HBED-iPSMA
Clinical Study IdentifierNCT04030338
SponsorMemorial Sloan Kettering Cancer Center
Last Modified on27 January 2021


Yes No Not Sure

Inclusion Criteria

Patients with histologically confirmed prostate cancer, that is either: newly diagnosed OR progressive as defined by standard PCWG3 criteria. note that metastatic disease is defined by either bone scintigraphy or by CT or MRI, or a combination of these tests, but not exclusively by molecular imaging criteria
Patients with newly diagnosed localized or metastatic prostate cancer are
eligible, provided standard imaging (either bone scintigraphy, CT or MRI)
demonstrates evidence of radiographic disease
Patient with progressive disease that is non-metastatic are eligible by
biochemical progression: A minimum of three rising PSA values from a baseline
that are obtained 1 week or more apart, or 2 measurements 2 or more weeks
Patients with progressive disease that is metastatic are eligible either by
biochemical progression or radiographic progression or both
Patients are permitted to have had up to 2 months of prior hormonal therapy
before entering this trial (and many therapeutic trials) and therefore, their
progression criteria would apply to their pre-treatment imaging and PSA
Karnofsky performance status of >/= 50 (or ECOG/WHO equivalent)
Male (or transgender female) > 18 years of age
Patient must be able to understand and willing to sign a written informed consent document
Patient is anticipating starting a therapeutic strategy following imaging

Exclusion Criteria

Patient undergoing active treatment for non-prostate malignancy, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and non-invasive bladder cancer
Unable to lie flat, still or tolerate a PET scan
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note